Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Loupakis

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trialsC Cremolini, F Loupakis, G Masi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestC Cremolini, F Loupakis, C Antoniotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosisC Cremolini, M Di Bartolomeo, A Amatu, et al.
ESMO Open|July 16, 2021
Intratumor morphologic and transcriptomic heterogeneity in <sup>V600E</sup>BRAF-mutated metastatic colorectal adenocarcinomasV Angerilli, E Fontana, S Lonardi, et al.
The Pharmacogenomics Journal|December 24, 2008
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancerF Graziano, A Ruzzo, E Canestrari, et al.
The Pharmacogenomics Journal|February 12, 2014
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patientsF Loupakis, C Antoniotti, C Cremolini, et al.
British Journal of Cancer|July 16, 2009
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerF Loupakis, A Ruzzo, C Cremolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2011
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancerV Catalano, F Loupakis, F Graziano, et al.
British Journal of Cancer|May 6, 2015
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resectionM Schirripa, F Bergamo, C Cremolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2015
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trialsY Sunakawa, S Stintzing, S Cao, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trialsC Cremolini, F Loupakis, G Masi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestC Cremolini, F Loupakis, C Antoniotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosisC Cremolini, M Di Bartolomeo, A Amatu, et al.
ESMO Open|July 16, 2021
Intratumor morphologic and transcriptomic heterogeneity in <sup>V600E</sup>BRAF-mutated metastatic colorectal adenocarcinomasV Angerilli, E Fontana, S Lonardi, et al.
The Pharmacogenomics Journal|December 24, 2008
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancerF Graziano, A Ruzzo, E Canestrari, et al.
The Pharmacogenomics Journal|February 12, 2014
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patientsF Loupakis, C Antoniotti, C Cremolini, et al.
British Journal of Cancer|July 16, 2009
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerF Loupakis, A Ruzzo, C Cremolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2011
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancerV Catalano, F Loupakis, F Graziano, et al.
British Journal of Cancer|May 6, 2015
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resectionM Schirripa, F Bergamo, C Cremolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2015
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trialsY Sunakawa, S Stintzing, S Cao, et al.
Pageof 6